Wave provides POC for RNA editing platform; plus Surrozen, Pinteon and Minoryx 

Wave Life Sciences Ltd. (NASDAQ:WVE) unveiled on Wednesday preclinical proof-of-concept data for its RNA editing platform, which could indicate a technological pivot for the company following setbacks for two clinical Huntington disease antisense oligonucleotides candidates in March. Wave presented at the Jefferies Virtual Healthcare Conference data from an alpha-1 antitrypsin deficiency mouse modal showing its ADAR-mediated approach had an editing efficiency of up to 40% in the liver and led to a threefold increase in serum AAT levels.

A Nature Communications article from Surrozen Inc. suggests the regenerative medicine company is expanding its pipeline of Wnt-activating antibodies to include mimetics for bone loss and repair. The bispecific mimetics, which target multiple frizzled receptors and either LRP5 or LRP6, enhanced bone accrual in mice with osteoporosis or femoral fracture. Surrozen’s lead programs, due to enter the clinic next year, are for inflammatory bowel disease and severe alcoholic hepatitis. In April, the company announced plans to merge with a SPAC affiliated with Consonance Capital Management, with the aim of becoming a publicly listed biotech. ...